Blue Water Biotech announces collaboration with IQVIA

Blue Water Biotech (BWV) announced plans to establish a medical sales representative team with IQVIA (IQV) to market Blue Water’s commercial portfolio. This portfolio is highlighted by ENTADFI, a treatment for benign prostatic hyperplasia, and ZONTIVITY, a medication for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction or with peripheral arterial disease. In this collaboration, IQVIA and Blue Water will jointly work to build a sales team for Blue Water’s commercial products, covering key geographies that account for a large percentage of prescriptions in target markets, including urology and cardiology. Blue Water and IQVIA have agreed to commence certain activities on a provisional basis and are working towards finalizing a definitive agreement. “This collaboration with IQVIA is a promising step towards the launch of ENTADFI and the six assets we are acquiring,” said Joseph Hernandez, Chairman and Chief Executive Officer of Blue Water. “With decades of experience helping companies commercialize and market their products, we are thrilled to collaborate with IQVIA to build out our sales team and educate providers on the benefits of our products to get patients access to therapies they need.” In addition to the purchase of ENTADFI in April 2023, Blue Water recently signed an Asset Purchase Agreement on June 13, 2023 for the purchase of six FDA-approved assets across multiple indications, including cardiology, otic infections, and pain management.